Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation.
Dillon MT, Guevara J, Mohammed K, Patin EC, Smith SA, Dean E, Jones GN, Willis SE, Petrone M, Silva C, Thway K, Bunce C, Roxanis I, Nenclares P, Wilkins A, McLaughlin M, Jayme-Laiche A, Benafif S, Nintos G, Kwatra V, Grove L, Mansfield D, Proszek P, Martin P, Moore L, Swales KE, Banerji U, Saunders MP, Spicer J, Forster MD, Harrington KJ.
Dillon MT, et al. Among authors: banerji u.
J Clin Invest. 2024 Jan 16;134(2):e175369. doi: 10.1172/JCI175369.
J Clin Invest. 2024.
PMID: 37934611
Free PMC article.
Clinical Trial.